HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach (Companion Faculty Lecture)

<p class="MsoNormal">Featuring a slide presentation and related discussion from Dr John V Heymach, including the following topics:</p> <ul> <li>Overview of the biology and treatment landscape of HER2-mutant non-small cell lung cancer (NSCLC) (0:00)</li> <li>Datasets evaluating trastuzumab deruxtecan for HER2-mutant NSCLC (5:03)</li> <li>Clinical data with zongertinib for HER2-mutant NSCLC (6:35)</li> <li>Emerging data with sevabertinib for HER2-mutant NSCLC (14:41)</li> <li>Other investigational strategies being evaluated for HER2-mutant NSCLC (19:10)</li> <li>Summary of the current and future treatment landscape of HER2-mutant NSCLC (21:52)</li> </ul> <p class="MsoNormal"><a href= "http://m.researchtopractice.com/OncologyTodayHERAlteredNSCLC25/Presentation"> CME information and select publications</a></p>